cadherin-like genes to create a complex family of cell splicing in cotransfection assays. We conclude that surface adhesion proteins (Kohmura et al., 1998; Wu Nova-1 binds RNA in a sequence-specific manner to and Maniatis, 1999). The greatest degree of functional regulate neuronal pre-mRNA alternative splicing; the diversity can be generated when splicing of individual defect in splicing in Nova-1 null mice provides a model exons is regulated as independent events-a single mesfor understanding the motor dysfunction in POMA.
Histologic stains of older Nova-1 null mice revealed null mice that lived for an average of 2-3 weeks after birth. In these mice, the motor phenotype became para 4-fold increase in the number of pyknotic cells in the ventral region of the spinal cord relative to littermates ticularly pronounced after ‫01-7ف‬ days, with weakness and tremulousness, and with some mice showing clear ( Figures 2G and 2D-2F) . A survey of different areas revealed that the increase in pyknotic cells was most evisigns of atrophy in the hindlimbs. We examined GlyR␣2 splicing in postnatal day 16 dent in the ventral spinal cord, in specific brainstem (P16) Nova-1 null mice using several complementary To determine the reproducibility of these observamethods. First, RNA was RT-PCR amplified using primtions, we examined splicing to E3A and E3B in eight ers specific to GlyR␣2 E2 and GlyR␣2 E4. Reaction prodNova-1 null mice from six different litters and compared ucts were then digested with restriction enzymes that the results with splicing in normal littermates. In every specifically recognized sites either in E3A (SspI) or E3B case, RNA from Nova-1 null mice showed a decrease (BspMI). We confirmed that these enzymes uniquely recin the utilization of E3A relative to E3B ( Figure 3C ). These ognized E3A or E3B (with Ͼ98% specificity; Figure 3AII ) results are consistent with our transfection data (see and digested E2-E4 PCR products with these enzymes below), in which Nova-1 acts to enhance the utilization to determine E3A and E3B splicing efficiency (Figure of GlyR␣2 E3A, while in the absence of Nova-1 in vivo 3AI). In a second method, E3A-and E3B-specific primers there is a relative deficit in the ability of neurons to utilize were used under reaction conditions in which each the E3A splice site. primer showed absolute specificity for its respective exon ( Figure 3B ). In a third set of experiments, we perSpecificity of Splicing Defects in Nova-1 Null Mice formed RNase protection assays (see below). QuantitaWe next examined the specificity of the defect in GlyR␣2 tion of splicing using linear PCR reaction conditions splicing by comparing the splicing efficiency of six pregave highly reproducible results over a range of reaction viously described alternatively spliced neuronal tranconditions (input RNA, PCR cycle number) and between scripts ( Figure 4A ). Splicing of five of these transcripts animals (see below), and demonstrated that the ratio of was unchanged in Nova-1 null mice relative to their lit-E3A/E3B splicing was decreased in Nova-1 null mice relative to wild-type littermates by 2-fold.
termates, including clathrin light chain B (ClaB), agrin, mGluR1, ICH-1, and n-src. However, alternative splicing shown). In forebrain of wild-type versus null mice, we found no differences in alternative splicing for GlyR␣2, of the GABA A receptor ␥2 subunit was significantly al-GABA A ␥2L, or ClaB mRNA or in steady-state levels of tered in Nova-1 null mice. The GABA A ␥2 transcript is actin or the spinal motor neuron marker choline acetylwidely expressed in the brain, but the pre-mRNA is altertransferase (ChAT) ( Figure 5 ). We conclude that Nova-1 natively spliced to include a cassette exon, ␥2L, prefermediates a specific effect on the alternative splicing of entially in brainstem and spinal neurons (Zhang et al., GlyR␣2 and GABA A ␥2 receptor pre-mRNAs in a cell-1996). Examination of brainstem and spinal cord RNA autonomous manner. revealed a 2-fold difference in the E3A/E3B GlyR␣2 splicing ratio and nearly a 3-fold difference in the ␥2L/ ␥2S GABA A ␥2 splicing ratio in wild-type versus Nova-1 Genotype and Developmental Profile null mice, averaged over 11 and 9 litters, respectively of Splicing Changes ( Figure 4B ). Similar results were obtained with RNase
The level of Nova-1 protein varies in a dose-dependent protection assays (data not shown), although these remanner in wild-type mice relative to Nova-1 heterozysults were less reliable than RT-PCR in quantitating the gous and null mice ( Figure 1D ). To assess whether the low-abundance GlyR␣2 splice variants in a tissue samsplicing defects of GlyR␣2 and GABA A ␥2 RNAs were ple of high complexity, as anticipated (Foley et al., 1993) . dependent on the level of Nova-1 protein, we examined Although the GlyR␣2 and GABA A ␥2 genes are exthe utilization of these exons in mice as a function of pressed throughout the brain, Nova-1 expression is abNova-1 gene dosage. The GABA A ␥2L splicing defect sent in rostral structures, including the forebrain and varied from 1.5-fold in heterozygous mice to a 3-fold sensory thalamus (Buckanovich et al., 1996; Yang et al., change Nova-1 null littermates (Figures 6A and 6B). 1998; Figure 1D ). If aberrant GlyR␣2 E3A and GABA A GlyR␣2 E3A utilization was only abnormal in Nova-1 null ␥2L splicing results directly from the lack of Nova-1 in mice, suggesting differences in the degree to which neurons, splicing of these RNAs should be normal in the the Nova-1 protein is rate limiting for proper splicing of forebrain and abnormal in the spinal cord of individual GlyR␣2 and GABA A ␥2 pre-mRNAs.
Nova-1 null mice. Specific abnormalities in GlyR␣2 and
When we examined alternative splicing as a function GABA A ␥2 splicing were found in the spinal cord and of age, we found that utilization of the GABA A ␥2L increased in wild-type mice during the first 3 weeks of hindbrain but not the forebrain ( Figure 5 ; data not Figure 3C . Unlike the spinal cord, quantitation of phosphorimager data using RNA from forebrain revealed no differences in the ratio of GlyR␣2 E3A/E3B and ␥2L/␥2S GABA A exon usage between Nova-1 null animals and wild-type littermates. ClaB alternative splicing showed no null:wild-type difference in either spinal cord or forebrain. Quantitation revealed no differences in the steady-state levels of RNA encoding the motor neuron marker ChAT or actin in Nova-1 null spinal cord relative to wild-type.
Mouse Brain Nova Binds Specifically to (UCAUY) 3 RNA
To evaluate whether the GlyR␣2 splicing defect evident in Nova-1 null mice could be a direct action of Nova-1 on GlyR␣2 pre-mRNA, we first examined whether native 
Splicing in Cell Lines
We next examined whether Nova-1 is able to directly and that a deficiency in exon utilization first becomes apparent at P7 in Nova-1 null mice ( Figure 6C ). In Nova-1 act on GlyR␣2 pre-mRNA to regulate alternative splicing of the E3A/E3B exons. We generated a minigene conheterozygous mice, there was again an intermediate deficit in GABA A ␥2 usage evident at P7. The GlyR␣2 struct consisting of genomic DNA encoding GlyR␣2 E2, E3A, E3B, and E4 and several hundred nucleotides of E3A/E3B ratio was unchanged in P0-P4 Nova-1 null mice (Ͻ10% difference across multiple littermates) and intronic DNA on either side of these exons ( Figure 8A ). To allow us to determine whether Nova-1 acts directly thereafter differed by 2-fold (data not shown). on the GlyR␣2 intronic (UCAUY) 3 element, we also generon extracts of a neuroblastoma cell line, N2A, transfected with the wild-type (UCAU) or mutant (UAAU) ated a mutant minigene in which this element was mutated to the nonbinding (UAAUY) 3 sequence. These conGlyR␣2 minigene in the presence or absence of pcNova-1. A Nova-1 dose-dependent increase in splicing to E3A structs were then transfected into three different cell lines along with increasing amounts of a plasmid ex-(and compensatory decrease in E3B) is evident in cells transfected with the wild-type UCAU but not the mutant pressing Nova-1 (pcNova-1).
Nova-1 transfection mediated an increase in GlyR␣2 UAAU GlyR␣2 minigene. We demonstrated that Nova-1 was present in increasing amounts in cells transfected E3A splicing in each of the three cell lines tested. Figure  8B illustrates the results of splicing assays performed with increasing amounts of pcNova-1 by Western blot analysis ( Figure 8C ).
To confirm these results and analyze splicing to both E3A and E3B, we repeated independent transfection experiments in N2A cells ( Figure 8D ). In cells transfected with the wild-type UCAU GlyR␣2 minigene, Nova-1 reproducibly increased E3A splicing at the expense of E3B splicing. Nova-1 mediated a 2-fold increase in E3A utilization, an effect similar in magnitude to the decrease in the E3A/E3B splicing ratio seen in Nova-1 null mice (Figures 3 and 4) .
In N2A cells transfected with the mutant UAAU GlyR␣2 minigene, splicing to E3A was unchanged relative to the wild-type minigene ( Figure 8D ). In the presence of increasing amounts of Nova, a paradoxical increase in E3B, at the expense of E3A, was seen. While the mechanism underlying this observation is unclear, a possible additional effects were seen. In HeLa cells, the increase in E3A splicing was at the expense of E3B, while in 293T that Nova-1 functions to regulate alternative splicing in neurons by binding pre-mRNA in a sequence-specific cells the increase in E3A-spliced product was inversely proportional to a decrease in an aberrant spliced prodmanner to activate exon inclusion. Nova-1 present in brain extracts specifically cross-links the sequence uct that contained neither E3A nor E3B (E2-E4; data not shown). We also found that in cells transfected with the (UCAUY) 3 but not the mutant sequence (UAAUY) 3 , consistent with previous coimmunoprecipitation experimutant UAAU GlyR␣2 minigene, in the presence of Nova there was no increase in E3A splicing but again a paraments demonstrating that Nova-1 protein binds GlyR␣2 pre-mRNA in vivo. In cotransfection assays, GlyR␣2 predoxical increase in E3B splicing, and in the absence of Nova there was a small but consistent increase in E3A mRNAs harboring this (UCAUY) 3 sequence show a Nova-1 dose-dependent increase in utilization of the splicing that is unexplained. Taken together, these experiments demonstrate that Nova-1 is able to act directly alternatively spliced E3A, while mutant pre-mRNAs harboring the (UAAUY) 3 point mutant do not show this efto enhance the inclusion of GlyR␣2 E3A in cell lines and that this action is dependent on the integrity of the fect. In Nova-1 null mice, there is a reciprocal 2-fold decrease in the ratio of GlyR␣2 E3A relative to E3B intronic UCAU Nova binding site.
splicing. These data provide converging lines of evidence that Nova-1 regulates GlyR␣2 splicing by directly Discussion binding to the pre-mRNA in neurons. We also find a second specific defect in alternative Nova-1 Regulates Mammalian Tissue-Specific splicing in Nova-1 null mice, which is deficient inclusion Alternative Splicing of the GABA A ␥2L exon. The defective exon utilization We have combined biochemical and genetic apof ␥2L and GlyR␣2 E3A in Nova-1 null mice, together proaches to demonstrate that Nova-1 functions to reguwith the finding that Nova-1 enhanced E3A utilization in late alternative splicing in neurons and found that the heterologous cells, suggests that Nova-1 most likely absence of Nova-1 leads to neuronal death in spinal and brainstem neurons. We provide strong evidence acts to activate GlyR␣2 E3A and GABA A ␥2L exon inclu-sion in neurons. An alternative, and not entirely exclu-1996; Figures 1 and 2) . Therefore, the identification of Nova-1 as a splicing factor provides a mechanism by sive, possibility is that Nova-1 activates splicing indiwhich individual neurons can differentially regulate rectly by competing with a splicing inhibitor. Such an splicing in a manner qualitatively distinct from that of interpretation would be consistent with the observation other cell types. that Nova action can be antagonized by a newly discovIn previous studies of the mechanism of neuron-spe- 
